Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Olorinab · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Olorinab | DRUG | Olorinab active treatment for 8 weeks. |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Olorinab is an investigational small molecule being developed for Crohn's Disease, specifically for abdominal pain associated with the condition. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Olorinab is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The drug is currently in Phase 2 clinical development for Crohn's Disease.
Olorinab is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. One Phase 2 trial has been completed.
Olorinab has been studied in one completed Phase 2 clinical trial, registered as NCT03155945. This trial evaluated the tolerability, pharmacokinetics, and efficacy of Olorinab in participants with Crohn's Disease experiencing abdominal pain, enrolling 14 participants.
Yes, Olorinab is the same drug as APD371. The completed Phase 2 clinical trial NCT03155945 used the name APD371 in its title, and Olorinab is the current name for this investigational small molecule being developed by Pfizer.